Naturally repairing or reversing damage caused by degenerative disease

Frequency is pioneering a new class of small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy functional tissues and organs.


Sensorineural Hearing Loss (SNHL)

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FX-322 Phase 2a – 202 Study
Phase 2

Study of noise induced and sudden SNHL patients with mild to moderately severe acquired SNHL, ages 18 – 65

End of study read out in late Q2 2021

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FX-322 Phase 1b – 111 Study
Phase 1

Open-label safety study focused on administration conditions for FX-322. Subjects had mild to severe SNHL, ages 18 – 65

Study enrolled with 33 subjects, completed March 2021

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FX-322 Phase 1b – 112 Study
Phase 1

Study of mild to moderately severe age-related hearing loss patients, ages 66 – 85

Top line readout in May 2021

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
FX-322 Phase 1b – 113 Study
Phase 1

Study of patients with severe SNHL, ages 18 – 65

Readout planned for H2 2021


Multiple Sclerosis

DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Remyelination in Multiple Sclerosis
Preclinical

Clinical Trials Information

For more information on the phase 2a clinical trial for FX-322, please visit clinicaltrials.gov.

Expanded Access Policy

Learn about our expanded access policy.

Our Program for Sensorineural Hearing Loss

Advancing FX-322 into a Phase 2a clinical study for the most common form of hearing loss

Learn More

Our Program for Multiple Sclerosis

Discovery science focused on activating progenitor cells in the central nervous system to repair myelin

Learn More